Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO) announced that Phillip Samayoa will present a company overview at the Cell & Gene Meeting on the Mesa, virtually held from Oct. 12-16, 2020. The presentation will be available for on-demand viewing during the conference. Additionally, CEO Geoff McDonough, M.D., will participate in a panel discussion on gene delivery, accessible from Oct. 13. Generation Bio focuses on innovative, non-viral gene therapy for durable treatments of rare and prevalent diseases using proprietary technologies aimed at scalable and effective gene delivery.

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa, vice president of strategy and portfolio development, will present a company overview at the annual Cell & Gene Meeting on the Mesa. The presentation will be available for registered participants to view on demand throughout the conference, to be held virtually Oct. 12-16, at meetingonthemesa.com.

Geoff McDonough, M.D., Generation Bio’s president and chief executive officer, will participate in a panel on the future of gene delivery. That discussion will be available to view on demand on the conference website starting Oct. 13.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit generationbio.com.

Contact:

Investors 
Chelcie Lister 
THRUST Strategic Communications
chelcie@thrustsc.com
910-777-3049

Media 
Stephanie Simon 
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

FAQ

What is the date of the Cell & Gene Meeting on the Mesa where Generation Bio will present?

The Cell & Gene Meeting on the Mesa will be held virtually from October 12 to October 16, 2020.

Who will represent Generation Bio at the upcoming conference?

Phillip Samayoa will present a company overview, and CEO Geoff McDonough will participate in a gene delivery panel.

What is the focus of Generation Bio's gene therapy?

Generation Bio specializes in non-viral gene therapy aimed at providing durable, redosable treatments for various diseases.

When will the panel discussion featuring CEO Geoff McDonough be available?

The panel discussion will be available for on-demand viewing starting October 13, 2020.

What technologies does Generation Bio use for its gene therapy?

Generation Bio utilizes a proprietary high-capacity DNA construct, a cell-targeted lipid nanoparticle delivery system, and a scalable manufacturing process.